IMUX Immunic, Inc.
Company Analysis
Latest News
🟢 Immunic, Inc. is trading 5.5% up today, extending a multi-day rebound following analyst target updates
Immunic, Inc. is trading at $14.47 (+5.5%), extending a sharp multi-day rebound from levels near $12 seen earlier in June. • The move follows recent attention...
🟢 Immunic, Inc. is trading 5.9% up today, extending a sharp rebound from recent weakness
Immunic, Inc. is trading 5.9% up at $13.84, extending a sharp rebound that began earlier this week after prior weakness in the biotech and small-cap...
🟢 Immunic, Inc. is trading 10.1% up today on rebound after recent biotech and small-cap pressure
Immunic, Inc. is trading 10.1% up at $12.89 today as it rebounds from several down days and recent weakness in the biotech and small-cap sectors. • The stock...
🟢 Immunic, Inc. is trading 6.7% up today as shares rebound from recent pressure
Immunic, Inc. is trading 6.7% up at $12.49 as shares appear to be rebounding following recent biotech and small-cap pressure. • There are no fresh...
🔴 Immunic, Inc. is trading 5.3% down today as broad market sell-off pressures biotech
Immunic, Inc. is trading 5.3% down today at $11.61 as a broad risk-off environment pressures high-beta, small-cap biotech stocks. • The decline extends a...
🟢 Immunic, Inc. is trading 8.1% up today on a technical rebound after recent declines
Immunic, Inc. is trading 8.1% up at $13.25 in after-hours trading, rebounding from a recent multi-day slide. • The move appears driven by bargain hunting and...
🟢 Immunic, Inc. is trading 8.1% up today as it rebounds from recent weakness despite no clear catalyst
Immunic, Inc. is trading at $13.25 (8.1% up) in after-hours trading as the stock rebounds from recent weakness despite a lack of fresh company-specific...
🟢 Immunic, Inc. is trading 5.8% up today, rebounding from a two-day pullback amid broader market gains
Immunic, Inc. is trading at $12.76 (+5.76%), rebounding from a sharp two-day pullback despite a lack of company-specific news or regulatory updates. • The...
Immunic price target cut, yet analysts see massive 245% upside
Analysts revised the average one-year price target for Immunic, Inc. to $44.09 per share. This figure represents a 13.34% decrease from the previous estimate...
🔴 Immunic, Inc. is trading 0.1% down today amid biotech and rates-related volatility
Immunic, Inc. is trading at $12.78 (0.1% down) today amid ongoing biotech and rates-related volatility as investors digest recent sector-wide risk sentiment...
🔴 Immunic, Inc. is trading 0.1% down today amid broader biotech and rates-driven volatility
Immunic, Inc. is trading at $12.78 (0.1% down) in pre-market, remaining essentially flat versus the June 5 close of $12.77 following a period of high...
🟢 Immunic, Inc. is trading 9.6% up today amid broad biotech rebound
Immunic, Inc. is trading approximately 9.6% up in after-hours trading at $14.00 amid a broad biotech rebound following a rates-driven selloff. • The stock is...
🔴 Immunic, Inc. is trading 10.3% down today as rising Treasury yields pressure growth and biotech stocks
Immunic, Inc. is trading 10.3% down at $12.95 amid a broad risk-off move following stronger-than-expected U.S. jobs data. • The robust labor market report has...
🔴 Immunic, Inc. is trading 5.4% down today following stronger-than-expected U.S. jobs data
Immunic, Inc. is trading at $13.65 (down 5.4%) following a sharp sell-off in growth and risk assets triggered by a stronger-than-expected U.S. jobs report. •...
🟢 Immunic, Inc. is trading 6% up today with no clear company-specific catalyst found
Immunic, Inc. is trading at $14.97 (+5.65%) on no clear company-specific catalyst following a strong early-session move. • No major clinical updates,...
Immunic Presents Favorable Phase 2 Data for Vidofludimus Calcium in Progressive MS
Immunic, Inc. announced the presentation of additional data from its Phase 2 CALLIPER trial for its lead asset, vidofludimus calcium (IMU-838), in patients...